Technology Appraisal Committee Meeting (Committee B)

Minutes: Confirmed

Date and Time: Tuesday, 22 August 2017, 10am to 1pm

Venue: National Institute for Health and Care Excellence
10 Spring Gardens
London
SW1A 2BU

Present:
1. Dr Amanda Adler Present for all notes
2. Dr Sanjeev Patel Present for all notes
3. Professor John Cairns Present for all notes
4. Mr Mark Chapman Present for all notes
5. Mr Diar Fattah Present for all notes
6. Ms Susan Faulds Present for all notes
7. Mark Glover Present for all notes
8. Dr Sumeet Gupta Present for all notes
9. Mr Richard James Hoddes Present for all notes
10. Mr Christopher O'Regan Present for all notes
11. Professor Stephen Palmer Present for all notes
12. Dr Danielle Preedy Present for all notes
13. Ms Marta Soares Present for all notes
14. Dr Nicky Welton Present for all notes

In attendance:
Bashama Anjum Administrator, National Institute for Health and Care Excellence Present for all notes
Ahmed Elsada Technical Advisor, Technology Appraisals, National Institute for Health and Care Excellence Present for all notes
Elisabeth George Associate Director, National Institute for Health and Care Excellence Present for all notes
Anwar Jilani Technical Analyst, National Institute for Health and Care Excellence Present for all notes
Jeremy Powell Project Manager, National Institute for Health and Care Excellence Present for all notes
Isaac Corro Ramos Evidence Review Group, Kleijnen Systematic Present for notes 1 to 15
Dr Rob Riemsma
Evidence Review Group, Kleijnen Systematic Reviews
Present for notes 1 to 15

Professor Peter Clark
Present for all notes

Dr Graham Collins
Consultant Haematologist, Oxford University Hospital – clinical expert, nominated by Roche
Present for notes 1 to 13

Geraldine Mason
Patient expert, nominated by the Lymphoma Association
Present for notes 1 to 13

Professor Andrew Pettitt
Professor and Honorary Consultant Haematologist, University of Liverpool, Royal Liverpool and Broadgreen University Hospitals – clinical expert, nominated by the NCRI-ACP-RCP-RCR
Present for notes 1 to 13

Ms Kate Robinson
Patient expert, nominated by the Lymphoma Association
Present for notes 1 to 13

Non-public observers:

Helen Barnett
Senior Medical Editor, NICE
Present for all notes

Heidi Livingstone
Senior Public Involvement Advisor, Communications, NICE
Present for all notes

Edgar Masanga
Business Analyst, Resource Impact Assessment
Present for all notes

Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisal of obinutuzumab for untreated advanced follicular lymphoma [ID1020]

2. The Chair welcomed Mr Diar Fattah, Ms Susan Faulds and Mr Richard Hoddes to their first meeting as a member of the Appraisal Committee
3. Apologies were received from Dr Ray Armstrong, Dr Nigel De Kare Silver, Dr Sanjay Kinra, Dr Miriam McCarthy, Nigel Westwood and Dr Stuart Williams

Any other Business

4. The Committee were given an update on the progress of appraisals that had been discussed at previous meetings.

Appraisal of obinutuzumab for untreated advanced follicular lymphoma [ID1020]

Part 1 – Open session

5. The Chair welcomed the invited experts: Professor Peter Clark, Dr Graham Collins, Geraldine Mason, Professor Andrew Pettitt, Ms Kate Robinson, Isaac Corro Ramos and Dr Rob Riemsma to the meeting and they introduced themselves to the Committee.

6. The Chair welcomed company representatives from Roche to the meeting.

7. The Chair asked all Committee members to declare any relevant interests

7.1. Dr Amanda Adler, Dr Sanjeev Patel, Professor John Cairns, Mr Mark Chapman, Mr Dior Fattah, Ms Susan Faulds, Mark Glover, Dr Sumeet Gupta, Mr Richard James Hoddes, Mr Christopher O'Regan, Professor Stephen Palmer, Dr Danielle Preedy, Ms Marta Soares, Dr Nicky Welton all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of obinutuzumab for untreated advanced follicular lymphoma [ID1020].

8. The Chair asked all NICE Staff to declare any relevant interests.

8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of obinutuzumab for untreated advanced follicular lymphoma [ID1020].

9. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.

9.1. Professor Peter Clark, Geraldine Mason, Isaac Corro Ramos and Dr Rob Riemsma declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of obinutuzumab for untreated advanced follicular lymphoma [ID1020].

9.2. Dr Graham Collins declared a personal specific financial interest as he has received honoraria, speaking and consulting fees from Roche.
9.2.1. It was agreed that this declaration would not prevent Dr Collins from participating in this section of the meeting.

9.3. Professor Andrew Pettitt declared a personal specific financial interest as he has received research funding and honoraria from Roche.
9.3.1. It was agreed that this declaration would not prevent Professor Pettitt from participating in this section of the meeting.

9.4. Ms Kate Robinson declared a personal non-specific non-financial interest as she is part of the relevant NCRI clinical studies group.
9.4.1. It was agreed that this declaration would not prevent Ms Robinson from participating in this section of the meeting.

10. The Chair introduced the lead team, Dr Sanjeev Patel and Mark Chapman who gave presentations on the clinical effectiveness and cost effectiveness of obinutuzumab for untreated advanced follicular lymphoma [ID1020].

11. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

12. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

13. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

14. Discussion on confidential information continued. This information was supplied by the company.

15. The Chair then thanked the Evidence Review Group representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

16. The Committee continued to discuss the clinical and cost effectiveness of obinutuzumab for untreated advanced follicular lymphoma [ID1020].
16.1. The committee decision was based on consensus.

17. The Committee instructed the technical team to prepare the [Appraisal Consultation Document (ACD) in line with their decisions.

Date, time and venue of the next meeting

18. Wednesday, 20 September 2017, 10am to 5pm at National Institute for Health and Care Excellence, 10 Spring Gardens, London SW1A 2BU